{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:07Z","timestamp":1793212087708,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Evidence on the safety of newer biologics during pregnancy is limited. We aimed to assess the safety of ustekinumab and vedolizumab treatment during gestation on pregnancy and infant outcome. Furthermore, we evaluated the placental transfer of these agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a prospective, multicentre, observational study in consecutive women with inflammatory bowel disease exposed to ustekinumab or vedolizumab 2 months prior to conception or during pregnancy. Pregnancy, neonatal, and infant outcomes were evaluated and compared with the anti-tumour necrosis factor [TNF]-exposed control group. Drug levels were assessed in maternal and cord blood at delivery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 54 and 39 pregnancies exposed to ustekinumab and vedolizumab, respectively. In the ustekinumab group, 43 [79.9%] resulted in live births, and 11 [20.4%] led to spontaneous abortion. Thirty-five [89.7%] pregnancies on vedolizumab ended in a live birth, two [5.1%] in spontaneous, and two [5.1%] in therapeutic abortion. No significant difference in pregnancy outcome between either the vedolizumab or the ustekinumab group and controls was observed [p\u2005&amp;gt;0.05]. Similarly, there was no negative safety signal in the postnatal outcome of exposed children regarding growth, psychomotor development, and risk of allergy\/atopy or infectious complications. The median infant-to-maternal ratio of ustekinumab levels was 1.67 and it was 0.59 in vedolizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Use of ustekinumab and vedolizumab in pregnancy seems to be safe, with favuorable pregnancy and postnatal infant outcomes. Placental transfer differed between these two drugs, with ustekinumab having similar and vedolizumab having inverse infant-to-maternal ratio of drug levels compared with anti-TNF preparations.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjac086","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T11:38:12Z","timestamp":1655379492000},"page":"1808-1815","source":"Crossref","is-referenced-by-count":50,"title":["Safety of Ustekinumab and Vedolizumab During Pregnancy\u2014Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study"],"prefix":"10.1093","volume":"16","author":[{"given":"Katarina","family":"Mitrova","sequence":"first","affiliation":[{"name":"Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE a.s., Charles University in Prague, Prague , Czech Republic"},{"name":"Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital , Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Pipek","sequence":"additional","affiliation":[{"name":"Digestive Diseases Centre, Hospital AGEL Vitkovice , Ostrava , Czech Republic"},{"name":"2nd Department of Internal Medicine\u2014Gastroenterology and Geriatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc , Czech Republic"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ostrava , Ostrava , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bortlik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Ceske Budejovice, Ceske Budejovice , Czech Republic"},{"name":"Institute of Pharmacology, 1st Faculty of Medicine, Charles University in Prague , Prague , Czech Republic"},{"name":"Department of Internal Medicine, 1st Faculty of Medicine and Central Military Hospital , Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludek","family":"Bouchner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine in Pilsen, Charles University in Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Brezina","sequence":"additional","affiliation":[{"name":"Department of hepatogastroenterology, Institute for Clinical and Experimental Medicine , Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Douda","sequence":"additional","affiliation":[{"name":"2nd Department of Gastroenterology, University Hospital Hradec Kralove, Charles University\u2014Faculty of Medicine in Hradec Kralove , Hradec Kralove , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Drasar","sequence":"additional","affiliation":[{"name":"IBD centre Turnov, Liberec Regional Hospital, Liberec , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klvana","sequence":"additional","affiliation":[{"name":"Beskydy Gastrocentre, Hospital Frydek-Mistek , Fr\u00fddek-m\u00edstek , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Kohout","sequence":"additional","affiliation":[{"name":"Endoscopy, Internal Department, Pardubice Hospital , Pardubice , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaclav","family":"Leksa","sequence":"additional","affiliation":[{"name":"Department of Medicine 1st Faculty of Medicine Charles University and Military University Hospital, Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Minarikova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 1st Faculty of Medicine and Central Military Hospital , Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Novotny","sequence":"additional","affiliation":[{"name":"4th Internal Clinic, General University Hospital, Charles University, Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ostrava , Ostrava , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Skorpik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Jihlava , Jihlava , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ulbrych","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, St. Anne\u2019s University Hospital Brno , Brno , Czech Republic"},{"name":"SurGal Clinic , B rno , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Veinfurt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Karlovy Vary , Karlov Vary , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"Zborilova","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Karlovy Vary , Karlov Vary , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Lukas","sequence":"additional","affiliation":[{"name":"Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE a.s., Charles University in Prague, Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Duricova","sequence":"additional","affiliation":[{"name":"Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE a.s., Charles University in Prague, Prague , Czech Republic"},{"name":"Institute of Pharmacology, 1st Faculty of Medicine, Charles University in Prague , Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Czech IBD Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"2022120518040016000_CIT0001","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group.","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology"},{"key":"2022120518040016000_CIT0002","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cgh.2020.09.021","article-title":"Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis.","volume":"20","author":"Nielsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022120518040016000_CIT0003","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease.","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"2022120518040016000_CIT0004","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/00365521.2013.812141","article-title":"Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-\u03b1 therapy during pregnancy: three-centre study.","volume":"48","author":"Bortlik","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"2022120518040016000_CIT0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/apt.15539","article-title":"Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.","volume":"51","author":"Moens","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2022120518040016000_CIT0006","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/apt.16593","article-title":"Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study.","volume":"54","author":"Julsgaard","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"2022120518040016000_CIT0007","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/apt.16192","article-title":"Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.","volume":"53","author":"Wils","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2022120518040016000_CIT0008","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1093\/ecco-jcc\/jjz203.666","article-title":"Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn\u2019s disease and ulcerative colitis treated with ustekinumab.","volume":"14","author":"Geldhof","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2022120518040016000_CIT0009","doi-asserted-by":"crossref","first-page":"17562848211032790","DOI":"10.1177\/17562848211032790","article-title":"Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study.","volume":"14","author":"Mitrova","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2022120518040016000_CIT0010","article-title":"Update on the management of inflammatory bowel disease during pregnancy and breastfeeding.","volume":"1","author":"Restellini","year":"2020","journal-title":"Digestion"},{"key":"2022120518040016000_CIT0011","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ibd\/izy294","article-title":"Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicentre observation.","volume":"25","author":"Duricova","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2022120518040016000_CIT0012","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicentre European TEDDY Study.","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2022120518040016000_CIT0013","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/apt.16739","article-title":"Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.","volume":"55","author":"Flanagan","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2022120518040016000_CIT0014","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","article-title":"Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines.","volume":"16","author":"Beaulieu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022120518040016000_CIT0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection.","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjac086\/44449336\/jjac086.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/12\/1808\/47589622\/jjac086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/12\/1808\/47589622\/jjac086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T03:25:28Z","timestamp":1700709928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/12\/1808\/6609344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6,16]]},"published-print":{"date-parts":[[2022,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac086","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,6,16]]}}}